The Pediatric-to-Adult Transition in the ICU: Caring for the Young Adult

A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

The transition of young adults with childhood-onset chronic diseases from pediatric to adult intensive care represents a complex challenge requiring specialized knowledge and multidisciplinary coordination. Advances in pediatric medicine have resulted in over 90% of children with chronic conditions now surviving into adulthood, creating a growing population of young adults with diseases traditionally managed in pediatric settings. This review examines the critical care management of transitioning patients, with particular emphasis on congenital heart disease and cystic fibrosis, while addressing the unique communication and psychosocial needs of this vulnerable population.

---

Introduction

The adult intensivist increasingly encounters young adults with diseases once considered exclusively pediatric. This demographic shift, termed the "transition population," presents unique clinical, psychosocial, and ethical challenges. Unlike typical adult ICU patients, these individuals bring complex congenital anatomies, multiorgan involvement, and psychological frameworks shaped by lifelong medical engagement. Understanding their specific needs is paramount for optimal outcomes and represents an essential competency for modern critical care practice.

---

Managing Congenital Heart Disease Patients Presenting to Adult ICUs

Epidemiology and Scope

Approximately 1.4 million adults in the United States live with congenital heart disease (CHD), with nearly half classified as having moderate or complex lesions. The adult CHD population now exceeds the pediatric CHD population, yet fewer than 50% receive specialized care in adult congenital heart disease (ACHD) centers. Consequently, general adult ICUs must be prepared to manage these patients during acute decompensation, perioperative care, or pregnancy-related complications.

Understanding Altered Anatomy and Physiology

Pearl #1: Never assume normal cardiac anatomy. Always obtain prior operative reports, echocardiograms, and catheterization data before implementing management strategies.

The fundamental challenge in managing CHD patients lies in appreciating their unique cardiovascular physiology. Common scenarios include:

Single Ventricle Physiology (Fontan Circulation): These patients have undergone staged palliation resulting in passive pulmonary blood flow without a subpulmonary ventricle. The Fontan circulation operates with elevated central venous pressures (12-18 mmHg) and depends critically on low pulmonary vascular resistance. Standard ICU interventions can be catastrophic:

• Hack: Avoid positive pressure ventilation when possible; even modest PEEP (>5 cmH₂O) can dramatically reduce cardiac output by impeding venous return. If intubation is necessary, use low tidal volumes (4-6 mL/kg), minimal PEEP, and consider early extubation strategies.
• Maintain preload meticulously; these patients cannot increase cardiac output through heart rate or contractility alone.
• Treat arrhythmias aggressively, as they tolerate tachyarrhythmias and bradyarrhythmias poorly.

Transposition of the Great Arteries (TGA) with Atrial Switch (Mustard/Senning): The morphologic right ventricle supports the systemic circulation, with the tricuspid valve serving as the systemic AV valve. These patients develop right ventricular dysfunction, tricuspid regurgitation, and atrial arrhythmias.

• Oyster: The "normal" ejection fraction on echo may be misleading; these right ventricles function at lower ejection fractions than morphologic left ventricles. An EF of 40% may represent severe dysfunction.
• Avoid negative inotropes; use afterload reduction cautiously as systemic hypotension is poorly tolerated.

Eisenmenger Syndrome: Uncorrected left-to-right shunts eventually lead to pulmonary arterial hypertension with shunt reversal. These patients present with cyanosis and erythrocytosis.

• Pearl #2: Never perform phlebotomy for "hyperviscosity" unless symptomatic and hematocrit exceeds 65%. The elevated hemoglobin is compensatory; unnecessary phlebotomy causes iron deficiency and worsens hyperviscosity.
• Pulmonary vasodilators (sildenafil, bosentan, epoprostenol) are cornerstone therapies but must be initiated by specialists.
• Pregnancy is absolutely contraindicated (maternal mortality 30-50%).

Critical Care Management Strategies

Hemodynamic Monitoring: Standard Swan-Ganz catheters may be impossible to place in complex anatomy. Consider:

• Arterial catheters for beat-to-beat blood pressure monitoring
• Central venous access for CVP trending (though interpretation varies by lesion)
• Non-invasive cardiac output monitoring (pulse contour analysis, bioreactance)
• Frequent echocardiography by experienced sonographers

Anticoagulation Considerations: Many CHD patients require chronic anticoagulation for mechanical valves, Fontan circulation, or atrial arrhythmias. Collaborate early with hematology and cardiology regarding bridging strategies.

Arrhythmia Management:

• Hack: Obtain old ECGs for comparison; their "normal" may show dramatic axis deviation, conduction blocks, or paced rhythms.
• Atrial tachyarrhythmias are common and poorly tolerated; aggressive rate or rhythm control is essential.
• Maintain electrolyte homeostasis rigorously (K⁺ >4.0, Mg²⁺ >2.0).

Endocarditis Prophylaxis: These patients remain at lifelong high risk. Use appropriate antibiotic prophylaxis for procedures and maintain high suspicion for endocarditis with any fever or bacteremia.

Respiratory Management:

• Avoid hypoxemia and hypercarbia, which increase pulmonary vascular resistance
• Use non-invasive ventilation preferentially
• If intubated, target normocapnia and optimize FiO₂ delivery while minimizing mean airway pressures

Pearl #3: Early consultation with ACHD specialists is not optional—it's essential. These subspecialists possess nuanced understanding of individual patient anatomy and can prevent catastrophic management errors.

Pregnancy-Related Complications

Pregnancy in CHD patients represents a high-risk scenario requiring multidisciplinary management. Women with Eisenmenger syndrome, severe left ventricular outflow obstruction, or systemic ventricular dysfunction face the highest mortality risk. Hemodynamic changes of pregnancy (increased blood volume, decreased systemic vascular resistance, hypercoagulability) can precipitate acute decompensation during the peripartum period. Consider early arterial access, invasive monitoring, and delivery in centers with ACHD and maternal-fetal medicine expertise.

---

Cystic Fibrosis and Other Childhood Diseases in the Adult Critical Care Setting

Cystic Fibrosis: From Pediatric Disease to Adult Chronic Illness

Cystic fibrosis (CF), once fatal in childhood, now sees median survival exceeding 50 years thanks to CFTR modulator therapies. However, adult CF patients experience progressive multiorgan complications requiring critical care expertise beyond traditional pulmonology.

Acute Respiratory Failure in CF

Clinical Presentation: CF patients develop chronic airway infection (typically Pseudomonas aeruginosa, Burkholderia cepacia, Staphylococcus aureus, nontuberculous mycobacteria), bronchiectasis, and progressive obstructive lung disease. Acute exacerbations manifest with increased cough, sputum production, dyspnea, and declining lung function.

Microbiological Considerations:

• Pearl #4: Always reference prior sputum cultures; CF patients harbor multidrug-resistant organisms requiring tailored antibiotic regimens.
• Burkholderia cepacia complex predicts poor outcomes and may preclude lung transplantation at some centers
• Combination intravenous antibiotics are standard (usually β-lactam plus aminoglycoside or fluoroquinolone)
• Extended dosing intervals for aminoglycosides (7-10 mg/kg once daily) due to altered pharmacokinetics

Respiratory Management:

• Hack: Maximize airway clearance with vest therapy, directed coughing, and mucolytics (dornase alfa, hypertonic saline) even during mechanical ventilation
• Non-invasive positive pressure ventilation (NIPPV) is first-line for respiratory failure; avoid intubation when possible as extubation may be extremely difficult
• If intubated, perform frequent suctioning; consider bronchoscopy for mucus plugging
• Target oxygen saturations of 88-92% for most patients (many have chronic hypoxemia)

Oyster: Hemoptysis is common in CF but rarely life-threatening. Massive hemoptysis (>240 mL/24h) requires bronchial artery embolization. Never anticoagulate these patients without compelling indication.

CF-Related Diabetes (CFRD)

Nearly 50% of adults with CF develop diabetes due to pancreatic insufficiency and destruction of islet cells. CFRD differs from types 1 and 2 diabetes:

• Maintain blood glucose 90-180 mg/dL; avoid hypoglycemia
• Insulin is the only recommended therapy; metformin and SGLT2 inhibitors are contraindicated
• During acute illness, nutritional support is essential (CF patients require 120-150% of predicted caloric needs)

Liver Disease and Portal Hypertension

CF-related liver disease affects 30-40% of patients, manifesting as cirrhosis, portal hypertension, and variceal bleeding. Management parallels other cirrhotic populations but consider:

• Maintain nutrition aggressively (malnutrition accelerates hepatic decompensation)
• Fat-soluble vitamin supplementation (A, D, E, K)
• Standard variceal bleeding protocols apply

Pneumothorax Management

Pneumothorax complicates CF in 3-4% annually, typically occurring with advanced disease. Standard chest tube management applies, but:

• Hack: Avoid pleurodesis in potential transplant candidates as it complicates future surgery; consult transplant teams early
• Recurrent pneumothorax may necessitate VATS or transplant evaluation

Transplant Considerations

Pearl #5: Initiate transplant discussions early in critical illness. The window for successful transplantation narrows rapidly with acute decompensation.

Lung transplantation criteria for CF include:

• FEV₁ <30% predicted
• Rapid lung function decline
• Pulmonary hypertension
• Increasing antibiotic requirements
• Life-threatening hemoptysis
• Respiratory failure requiring mechanical ventilation

Bridge to transplant options include invasive and non-invasive ventilation, though outcomes decline precipitously with prolonged mechanical ventilation. ECMO bridging is controversial but increasingly utilized at high-volume centers.

Other Childhood Diseases in Adult ICU Settings

Sickle Cell Disease (SCD): Acute chest syndrome represents a leading cause of ICU admission and mortality. Distinguish from pneumonia (though both may coexist). Management includes:

• Oxygen supplementation targeting SpO₂ >95%
• Incentive spirometry and analgesia to prevent splinting
• Broad-spectrum antibiotics (cover atypicals)
• Transfusion strategy: Simple transfusion if Hgb <9 g/dL; exchange transfusion for severe disease or rapid progression (target HbS <30%)
• Early hematology consultation
• Hack: Avoid over-hydration; SCD patients are prone to pulmonary edema

Muscular Dystrophies: Duchenne and Becker muscular dystrophy patients survive into adulthood with cardiomyopathy and restrictive lung disease. Key management points:

• Many use chronic non-invasive ventilation; continue during hospitalization
• Avoid succinylcholine (risk of rhabdomyolysis and hyperkalemia)
• Cardiomyopathy requires standard heart failure management
• Cough-assist devices and mechanical insufflation-exsufflation aid secretion clearance

Spina Bifida: Adults with spina bifida face neurogenic bladder, latex allergy, and shunt-dependent hydrocephalus.

• Pearl #6: Always use latex-free equipment
• High index of suspicion for shunt malfunction with altered mental status
• Urological complications common; early urology consultation for any genitourinary concerns

---

Communication and Psychosocial Support for Young Adults and Their Families

The Developmental Context

Young adults (ages 18-30) navigate a critical developmental period characterized by identity formation, autonomy development, and establishment of adult relationships. For those with chronic childhood illness, this transition is further complicated by medical complexity, psychological burden, and disrupted normal developmental trajectories.

Challenges in the Transition Population

Medical Complexity: These patients possess sophisticated knowledge of their disease developed over years yet may lack understanding of adult healthcare systems, insurance navigation, or self-advocacy skills traditionally developed during healthy adolescence.

Psychological Burden: Chronic illness during childhood and adolescence increases risks of depression, anxiety, post-traumatic stress, and adjustment disorders. ICU admission may represent loss of hard-won stability and trigger existential distress.

Social Isolation: Medical demands often limit educational opportunities, employment, and peer relationships, resulting in smaller support networks compared to healthy young adults.

Family Dynamics: Parents of children with chronic illness develop expertise as medical advocates and decision-makers. The transition to adult care requires renegotiating roles, which may be incomplete when critical illness strikes.

Communication Strategies

Pearl #7: Address the patient directly, even when parents are present. Use language that respects their adult status while acknowledging their expertise in their disease.

Establishing the Primary Relationship: Begin each interaction by clarifying who the patient wants involved in medical discussions. While respecting parental concern, center the patient as the primary decision-maker unless cognitive limitations exist. Sample opening: "I'd like to understand how you prefer to discuss your medical care. Do you want your parents involved in all discussions, or are there times you'd prefer to talk with me alone?"

Acknowledging Expertise: These patients are experts in their disease. Validating their knowledge builds therapeutic alliance: "You've lived with this your whole life—help me understand what's normal for you and what concerns you about what's happening now."

Avoiding Pediatric Language: Eliminate terms like "honey," "sweetie," or references to parents as "mom and dad" without patient's explicit preference. Speak as you would to any competent adult.

Managing Parental Anxiety: Parents face profound distress when their child enters adult critical care. Acknowledge their expertise while redirecting to the patient:

• "I can see you've been instrumental in managing [patient name]'s care. As we move forward, I'll be primarily directing questions to [patient name], but I value your input when they want you involved."
• Offer scheduled family meetings to address parental concerns without undermining patient autonomy

Hack: Schedule separate conversations with patient and family if conflict arises around decision-making or information sharing. Clarify the patient's wishes privately before engaging in family discussions.

Developmental-Stage-Appropriate Communication

Young adults vary in developmental maturity, medical literacy, and coping capacity. Tailor communication:

For Younger Patients (18-22): May benefit from:

• More frequent check-ins
• Explanation of ICU routines and expectations
• Permission to ask questions without judgment
• Acknowledgment that this experience differs from pediatric care

For Older Patients (23-30): Often prefer:

• Direct, efficient communication
• Greater autonomy in decision-making
• Recognition of competing life responsibilities (work, relationships, finances)
• Realistic prognosis discussions

Addressing Goals of Care

Pearl #8: Initiate goals-of-care conversations early, before crisis mandates urgent decisions. Frame discussions around quality of life, not just quantity.

Young adults with chronic illness have often contemplated mortality more than healthy peers but may not have articulated preferences. Useful prompts include:

• "Help me understand what gives your life meaning and what you hope for in your future."
• "Have you thought about what medical treatments you would or wouldn't want if your health deteriorated?"
• "If your health doesn't improve, what would be most important to you?"

Navigating Family Disagreements: When patients and families disagree about treatment goals, clarify:

1. Patient's decision-making capacity (formal assessment if unclear)
2. Patient's explicitly stated preferences
3. Duty to patient supersedes parental preferences for competent adults

Involve palliative care and ethics consultation early when conflicts arise.

Psychosocial Support Interventions

Multidisciplinary Team Engagement:

• Social work: Assess support systems, financial concerns, insurance coverage, and connect with community resources
• Psychology/psychiatry: Screen for depression, anxiety, PTSD; provide coping strategies and consider pharmacologic intervention when indicated
• Child life specialists: Some institutions extend child life services to young adults; these specialists understand chronic illness's developmental impact
• Spiritual care: Explore existential and spiritual concerns regardless of religious affiliation

Peer Support: Connect patients with peer support groups (many disease-specific organizations offer young adult programs). Peer mentorship provides validation that medical teams cannot replicate.

Maintaining Normalcy:

• Allow personal items, photographs, and music in the ICU
• Facilitate video calls with friends when appropriate
• Encourage families to maintain normal conversation topics, not only medical discussions
• Hack: Coordinate care to allow consolidated sleep periods; chronic illness patients often experience poor sleep quality at baseline

Supporting Parents: Parents face role ambiguity, grief, and helplessness. Interventions include:

• Acknowledging their lifelong caregiving role while supporting new dynamics
• Providing specific tasks (coordinating visitors, liaising with extended family) to channel their need to help
• Connecting with parent support organizations
• Respite periods encouraged (parents may resist leaving)

Addressing End-of-Life Care

When transition to palliative care becomes appropriate, young adults and families face unique grief. Death in young adulthood represents "off-time" mortality, violating expected life trajectories. Compassionate end-of-life care includes:

Developmentally Appropriate Legacy Work:

• Written letters or video messages to loved ones
• Completion of "unfinished business" (relationship mending, expressing gratitude)
• Life review emphasizing accomplishments despite illness burden
• Memory-making with photography or handprint molds

Family-Centered Care:

• Liberal visitation policies
• Space for siblings (often forgotten grievers)
• Bereavement support referrals
• Follow-up after death (condolence cards, optional bereavement meetings)

Oyster: Withdrawal of life support in young adults generates profound moral distress among healthcare teams. Debrief with staff after difficult cases; normalize emotional responses and reinforce ethical appropriateness of honoring patient preferences.

---

Conclusion

The pediatric-to-adult transition population represents a growing and complex cohort in adult critical care. Success requires more than disease-specific knowledge—it demands appreciation of altered anatomy and physiology, understanding of developmental psychology, and commitment to patient-centered communication. By integrating specialized medical expertise with developmentally appropriate psychosocial support, intensivists can optimize outcomes while honoring the unique experiences and perspectives of young adults navigating critical illness.

The adult ICU must evolve to embrace this population with curiosity rather than apprehension. Each encounter offers opportunity for learning and for providing compassionate, expert care to patients who have demonstrated remarkable resilience throughout their lives. As the transition population continues to expand, developing institutional protocols, fostering subspecialty collaborations, and pursuing ongoing education will ensure that young adults receive the sophisticated, holistic care they deserve.

---

Key Pearls Summary

1. Always obtain prior records before managing CHD patients
2. Never perform routine phlebotomy for erythrocytosis in Eisenmenger syndrome
3. Early ACHD consultation is mandatory, not optional
4. Reference prior cultures in CF patients for antibiotic selection
5. Initiate transplant discussions early in critical illness
6. Use latex-free equipment for spina bifida patients
7. Address young adult patients directly, respecting their autonomy
8. Begin goals-of-care conversations early, before crisis

---

References

1. Marelli AJ, Ionescu-Ittu R, Mackie AS, et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749-756.

2. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Circulation. 2019;139(14):e698-e800.

3. Gewillig M, Brown SC. The Fontan circulation after 45 years: update in physiology. Heart. 2016;102(14):1081-1086.

4. Cystic Fibrosis Foundation Patient Registry. 2022 Annual Data Report. Bethesda, MD; 2023.

5. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.

6. Moran A, Pillay K, Becker DJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):64-74.

7. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.

8. Gabriel P, McManus M, Rogers K, White P. Outcome evidence for structured pediatric to adult health care transition interventions: a systematic review. J Pediatr. 2017;188:263-269.

9. White PH, Cooley WC. Supporting the Health Care Transition From Adolescence to Adulthood in the Medical Home. Pediatrics. 2018;142(5):e20182587.

10. Sawicki GS, Lukens-Bull K, Yin X, et al. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ—Transition Readiness Assessment Questionnaire. J Pediatr Psychol. 2011;36(2):160-171.

11. Broberg CS, Hinton RB, Rosenkranz E, et al. Pregnancy in Women With Adult Congenital Heart Disease. JACC Heart Fail. 2020;8(5):371-382.

12. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819.

13. Hayes D Jr, Higgins RS, Kirkby S, et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation. Am J Respir Crit Care Med. 2014;190(12):1456-1464.

14. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord. 2003;13(10):804-812.

15. Bomba F, Herrmann-Garitz C, Schmidt J, Schmidt S, Thyen U. An assessment of the experiences and needs of adolescents with chronic conditions in transitional care: a qualitative study to develop a patient education program. Health Soc Care Community. 2017;25(2):652-666.

---

Corresponding Author Declaration: This manuscript represents expert consensus and literature review intended for educational purposes in critical care medicine training programs.

 

Neuro-Monitoring for the Non-Neurologist: Beyond the Pupil Exam

A Comprehensive Review for the Critical Care Physician

Dr Neeraj Manikath , claude.ai

---

Abstract

Neurological monitoring in the intensive care unit extends far beyond traditional clinical examination. As critical care physicians increasingly manage complex neurological emergencies, proficiency in advanced neuromonitoring modalities becomes essential. This review provides a practical framework for non-neurologist intensivists to utilize continuous electroencephalography (cEEG), invasive intracranial pressure (ICP) monitoring, and transcranial Doppler (TCD) ultrasonography. We emphasize actionable interpretations, clinical pearls, and evidence-based protocols that can be immediately implemented at the bedside.

Keywords: Neuromonitoring, non-convulsive status epilepticus, intracranial pressure, transcranial Doppler, critical care

---

Introduction

The pupil examination, while fundamental, represents merely the tip of the neurological assessment iceberg in critically ill patients. Modern neuromonitoring technologies have revolutionized our ability to detect secondary brain injury before irreversible damage occurs. However, these modalities remain underutilized, often due to knowledge gaps among non-neurologist intensivists. This review demystifies three cornerstone neuromonitoring techniques, providing the critical care physician with practical tools to enhance neuroprotection in their ICU.

---

Continuous EEG Monitoring: Identifying Non-Convulsive Status Epilepticus

The Hidden Epidemic

Non-convulsive status epilepticus (NCSE) affects approximately 8-48% of critically ill patients, depending on the population studied, yet remains clinically occult in the majority of cases.^1,2 Unlike convulsive status epilepticus, NCSE presents with subtle or absent motor manifestations, making it a diagnostic chameleon that masquerades as encephalopathy, coma, or unexplained altered mental status.

Clinical Pearl: The "Unexplained Encephalopathy" Red Flag

Any patient with unexplained encephalopathy or coma disproportionate to their metabolic derangements should be considered for cEEG monitoring. High-risk populations include post-cardiac arrest patients, those with CNS infections, traumatic brain injury, intracerebral hemorrhage, and critically ill patients with altered mental status following clinical or electrographic seizures.³

Indications for cEEG in the ICU

The 2015 consensus statement from the American Clinical Neurophysiology Society provides clear guidance:⁴

Tier 1 (Highest Priority):

• Persistent altered mental status following clinical seizure
• Suspected NCSE in comatose patients
• Pharmacological paralysis with suspicion for seizures

Tier 2 (Moderate Priority):

• Unexplained encephalopathy in high-risk populations
• Periodic discharges on routine EEG
• Monitoring response to anti-seizure therapy

Practical Interpretation for the Non-Neurologist

While comprehensive EEG interpretation requires specialized training, intensivists should recognize critical patterns:

1. Rhythmic Delta Activity (RDA)

• Frequency: 0.5-3 Hz, generalized or focal
• Oyster: Not all RDA is seizure activity, but it represents an "ictal-interictal continuum" requiring neurologist consultation
• Hack: If associated with clinical changes (eye deviation, automatisms, vital sign fluctuations), treat empirically while awaiting expert review

2. Lateralized Periodic Discharges (LPDs)

• Sharp waves or spikes occurring at regular intervals (0.5-2 Hz)
• Pearl: LPDs carry ~50% risk of associated seizures; aggressive treatment may be warranted even without definitive electrographic seizures⁵

3. Generalized Periodic Discharges (GPDs)

• Often seen post-cardiac arrest or in metabolic encephalopathy
• Oyster: GPDs are not necessarily seizures, but may indicate severe cortical injury and poor prognosis

4. Electrographic Seizures/Status Epilepticus

• Evolution in frequency, morphology, and distribution
• Duration >10 minutes or recurrent seizures without recovery = status epilepticus
• Critical Action: Initiate treatment immediately; neuronal injury begins within 30-60 minutes⁶

The "5-Minute Intensivist Review" Protocol

Step 1: Assess for asymmetry (suggests focal pathology) Step 2: Look for rhythmic activity (any rhythmic pattern >1 Hz is suspicious) Step 3: Check for evolution (changing frequency/amplitude suggests seizure) Step 4: Correlate with clinical state (does stimulation change the pattern?) Step 5: When in doubt, consult and treat empirically

Treatment Pearls

First-line: Levetiracetam (1500-3000 mg IV) or fosphenytoin (20 mg PE/kg) are ICU-friendly options with favorable side effect profiles⁷

Second-line: Consider valproate, lacosamide, or benzodiazepine infusions

Refractory NCSE: Continuous infusions (midazolam, propofol, pentobarbital) titrated to burst-suppression pattern with 10-20 second inter-burst intervals⁸

Hack: Always load with a long-acting agent before starting infusions to prevent breakthrough seizures during weaning

Duration of Monitoring

Minimum: 24 hours for high-risk populations (85% of seizures detected)⁹ Optimal: 48-72 hours (captures 95% of seizures) Continue: If seizures detected, continue 24 hours beyond last electrographic seizure

---

Invasive ICP Monitoring: Indications and Interpretation for the Intensivist

The Rationale: Cerebral Perfusion Pressure Management

Intracranial pressure monitoring remains controversial, with no definitive mortality benefit demonstrated in randomized trials.¹⁰ However, the absence of mortality benefit does not equate to futility. ICP monitoring provides crucial physiological data enabling individualized cerebral perfusion pressure (CPP) management and early detection of evolving mass lesions.

Indications: When to Place a Monitor

Evidence-Based Indications (Brain Trauma Foundation Guidelines):¹¹

Severe TBI (GCS ≤8):

• Abnormal CT scan (hematomas, contusions, edema, compressed cisterns)
• Normal CT but ≥2 of: age >40, motor posturing, systolic BP <90 mmHg

Other Common Indications:

• Aneurysmal subarachnoid hemorrhage with poor-grade (Hunt-Hess 3-5)
• Large hemispheric strokes at risk for malignant edema
• Intracerebral hemorrhage requiring surgical intervention
• CNS infections with hydrocephalus or mass effect
• Fulminant hepatic failure with grade 3-4 encephalopathy¹²

Device Selection: Understanding Your Options

External Ventricular Drain (EVD):

• Advantages: Gold standard accuracy, therapeutic CSF drainage, can recalibrate
• Disadvantages: Infection risk (8-10%)¹³, requires patient positioning, can occlude
• Pearl: Zero reference at the tragus or external auditory meatus in the midaxillary line

Intraparenchymal Monitors (e.g., Codman, Licox):

• Advantages: Easier placement, lower infection risk, can use in coagulopathy
• Disadvantages: Cannot recalibrate (drift over time), no therapeutic benefit, more expensive
• Hack: Consider for posterior fossa pathology where EVD placement is risky

Interpretation: Beyond the Number

Normal ICP: 5-15 mmHg (7-15 mmHg is commonly cited in neuro-ICU) Treatment Threshold: >20-22 mmHg sustained for >5 minutes¹¹

Oyster: ICP is not a static number – analyze waveform morphology and trends

ICP Waveform Analysis: The P1-P2-P3 Rule

Normal Waveform:

• P1 (percussion wave): Arterial pulsation
• P2 (tidal wave): Brain compliance
• P3 (dicrotic wave): Venous pulsation
• Normal pattern: P1 > P2 > P3

Abnormal Compliance:

• P2 > P1: Indicates decreased intracranial compliance, precursor to intracranial hypertension¹⁴
• Pearl: This occurs BEFORE sustained ICP elevation – early warning sign!

The Pressure-Volume Curve: Understanding Compliance

Hack: Think of the cranium as a full glass of water – initially, you can add drops without overflow (compensation), but once full, any additional volume causes dramatic pressure rises (decompensation)

Clinical Application: Patients with P2>P1 are on the steep part of the curve – even minor insults (suctioning, agitation, hypercapnia) can cause dangerous ICP spikes

CPP-Targeted Therapy: The Modern Approach

Cerebral Perfusion Pressure (CPP) = MAP - ICP

Target CPP: 60-70 mmHg for most patients¹¹

• Lower targets (50-60): May be appropriate in older patients or when cerebral autoregulation is intact
• Higher targets (>70): Consider in young TBI patients or when vasospasm is present

Oyster: CPP is more important than isolated ICP values – a patient with ICP 25 and MAP 110 (CPP 85) may tolerate this better than ICP 20 and MAP 70 (CPP 50)

Stepwise ICP Management Protocol

Tier 1 (First-line interventions):

1. Head of bed elevation: 30-45 degrees (improves venous drainage)
2. Maintain neck neutrality: Avoid jugular compression
3. Adequate sedation/analgesia: Prevents ICP spikes from agitation
4. Osmotic therapy:
   • Mannitol 0.25-1 g/kg (beware rebound, maintain serum osmolality <320 mOsm/L)
   • Hypertonic saline 23.4% (30 mL bolus) or 3% infusion (target Na 145-155)¹⁵
5. EVD drainage: If available, drain 2-5 mL CSF

Pearl: Hypertonic saline is superior to mannitol in traumatic brain injury and doesn't cause osmotic diuresis/hypotension¹⁶

Tier 2 (Refractory intracranial hypertension):

1. Hyperventilation: Target PaCO2 30-35 mmHg (temporary measure only, causes cerebral vasoconstriction)
2. Barbiturate coma: Pentobarbital bolus 10 mg/kg over 30 min, then 5 mg/kg/hr × 3, then 1 mg/kg/hr¹⁷
3. Decompressive craniectomy: Definitive intervention for refractory ICP

Hack: Before escalating to Tier 2, ensure adequate CPP (MAP optimization), normothermia, and eucapnia – these simple measures are often overlooked!

Troubleshooting: When ICP Values Don't Make Sense

Dampened Waveform:

• Causes: Clot in catheter, catheter against brain tissue, system air bubble
• Action: Flush EVD (if safe) or reposition patient; consider replacing monitor

Falsely Low ICP:

• Causes: Improperly zeroed, disconnection, catheter migration
• Action: Re-zero, check connections, obtain neuroimaging

Pressure Dissociation (EVD vs. parenchymal):

• Oyster: Up to 5 mmHg difference is acceptable; larger discrepancies suggest compartmentalization (requires neurosurgical consultation)

---

The Role of Transcranial Doppler in Vasospasm and Brain Death

Transcranial Doppler: The Bedside Vascular Window

Transcranial Doppler (TCD) ultrasonography provides real-time, non-invasive assessment of cerebral blood flow velocities through the transtemporal, transorbital, and suboccipital windows. While operator-dependent, TCD offers unique physiological insights unavailable through other modalities.

Technical Fundamentals for the Intensivist

Acoustic Windows:

• Transtemporal: Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA) – depth 30-65 mm
• Transorbital: Ophthalmic artery, internal carotid siphon – depth 40-60 mm
• Suboccipital: Vertebral and basilar arteries – depth 60-120 mm

Normal Values:

• MCA: 50-80 cm/sec (mean flow velocity)
• ICA: 40-60 cm/sec
• Basilar: 30-60 cm/sec

Pearl: Age-related decline occurs – subtract 10 cm/sec for patients >60 years

Application 1: Vasospasm Detection in Subarachnoid Hemorrhage

Delayed cerebral ischemia (DCI) affects 30% of aneurysmal SAH patients, typically occurring days 4-14 post-hemorrhage.¹⁸ TCD provides daily surveillance for vasospasm, the primary mechanism of DCI.

Vasospasm Diagnostic Criteria:

MCA Vasospasm:

• Mild: Mean velocity 120-150 cm/sec
• Moderate: 150-200 cm/sec
• Severe: >200 cm/sec¹⁹

Lindegaard Ratio (LR) = MCA velocity / Extracranial ICA velocity:

• Normal: <3
• Vasospasm: >3
• Severe vasospasm: >6

Oyster: Elevated velocities alone can be caused by hyperdynamic circulation (fever, anemia) – the Lindegaard ratio distinguishes true vasospasm from hyperemia

Hack: If you lack extracranial ICA measurements, an MCA velocity >200 cm/sec is 97% specific for angiographic vasospasm²⁰

Daily TCD Surveillance Protocol

Timing: Daily TCD from post-bleed day 3 through day 14 Concerning Trends:

• Velocity increase >50 cm/sec in 24 hours
• Lindegaard ratio >3
• Absolute velocities crossing thresholds above

Clinical Correlation:

• Symptomatic vasospasm: Velocity elevation PLUS new focal deficits or confusion
• Asymptomatic vasospasm: Velocity elevation WITHOUT clinical changes

Management Pearls

Mild-Moderate Vasospasm:

1. Induced hypertension: Increase MAP by 10-20% (avoid excessive hypertension in unsecured aneurysms)
2. Maintain euvolemia: Normal saline maintenance (not hypervolemia – outdated practice)²¹
3. Consider nimodipine optimization: Ensure receiving scheduled 60 mg q4h PO/NG

Severe or Symptomatic Vasospasm:

1. Endovascular intervention: Intra-arterial vasodilators (verapamil, nicardipine) or angioplasty²²
2. Hypertensive therapy: Aggressive MAP augmentation (phenylephrine or norepinephrine)
3. Pearl: Don't wait for angiography confirmation if clinical suspicion high – empiric hypertension can be life-saving

Hack: Pre-emptive angiography and prophylactic intra-arterial therapy is controversial but consider in high-risk patients (poor-grade SAH, thick cisternal blood)

Application 2: Brain Death Determination

TCD serves as an ancillary test when clinical brain death examination is incomplete or confounded (cervical spine injury preventing apnea test, hemodynamic instability, severe facial trauma).

TCD Findings in Brain Death:

Classic Pattern – Reverberating Flow:

• Systolic spike: Small forward flow
• Diastolic reversal: Equal magnitude backward flow
• Net flow: Approximately zero

Alternative Patterns:

• Systolic spikes only: Small systolic peaks without diastolic flow
• No signal: Complete absence of flow (occurs late; less reliable if early)

Diagnostic Criteria (requires 2 arteries):²³

• Reverberating flow or systolic spikes in bilateral MCAs OR
• One MCA plus one basilar/vertebral artery
• Duration: Persist for 30 minutes of continuous recording

Oyster: TCD cannot diagnose brain death alone – it's an ancillary test that must be combined with clinical criteria

Pearls:

• Timing: May become positive before clinical brain death exam – patience is required
• False negatives: Inadequate temporal windows (10-20% of population), early in disease course
• False positives: Severe intracranial hypertension without complete brain death

Beyond Vasospasm and Brain Death: Emerging TCD Applications

Autoregulation Assessment:

• Monitoring cerebrovascular reactivity to guide blood pressure targets
• Technique: Measure change in cerebral blood flow velocity in response to spontaneous or induced MAP changes
• Pearl: Impaired autoregulation suggests CPP-targeted therapy should target higher CPP values²⁴

Emboli Detection:

• High-intensity transient signals (HITS) identify microemboli
• Applications: Cardiac surgery, carotid stenosis, endocarditis
• Hack: >50 HITS in 1 hour during carotid endarterectomy predicts stroke risk²⁵

Intracranial Pressure Estimation:

• Pulsatility Index (PI) = (Peak systolic velocity - End diastolic velocity) / Mean velocity
• PI >1.2-1.4: Suggests elevated ICP (>20 mmHg)²⁶
• Oyster: Not reliable enough to replace invasive ICP monitoring, but useful for non-invasive trend monitoring

---

Multimodal Neuromonitoring: The Integrated Approach

Modern neurointensive care is moving toward multimodal monitoring, combining ICP, cEEG, TCD, brain tissue oxygenation (PbtO2), and microdialysis to create a comprehensive physiological picture. While beyond the scope of this review, intensivists should recognize that no single monitor tells the complete story.

The "Neuro-Vital Signs" Concept: Just as we don't rely solely on blood pressure or heart rate, neurological management requires synthesizing multiple data streams. The pupil exam remains foundational, but advanced neuromonitoring provides the granularity necessary for neuroprotection in the 21st-century ICU.

---

Practical Implementation: Building a Neuromonitoring Program

For ICUs Beginning Neuromonitoring:

1. Start with cEEG: Highest yield, immediate application, identify NCSE
2. Develop protocols: Standardized order sets reduce practice variation
3. Education: Monthly case conferences reviewing EEG, ICP, and TCD findings
4. Quality metrics: Track time-to-EEG, ICP monitoring in eligible patients, TCD compliance in SAH
5. Collaboration: Partner with neurology/neurosurgery for real-time consultation and teaching

Hack: Assign "neuromonitoring champions" among nursing and physician staff to maintain competency and enthusiasm

---

Conclusion

The pupil examination, while indispensable, represents only the beginning of comprehensive neurological assessment in critically ill patients. Continuous EEG monitoring identifies the hidden epidemic of non-convulsive status epilepticus, potentially preventing irreversible neuronal injury. Invasive ICP monitoring, when properly indicated and interpreted, guides cerebral perfusion management and detects evolving mass lesions. Transcranial Doppler provides a non-invasive window into cerebral hemodynamics, detecting vasospasm and confirming brain death.

For the non-neurologist intensivist, mastery of these modalities transforms neurological management from reactive to proactive. While specialized expertise enhances interpretation, the fundamental concepts and actionable interventions outlined in this review empower all critical care physicians to implement evidence-based neuromonitoring. As we advance toward personalized, precision medicine in neurocritical care, these tools will become increasingly essential in every ICU.

The future of neurocritical care is multimodal, data-driven, and individualized – and it begins with the motivated intensivist at the bedside.

---

Key Takeaway Pearls

1. NCSE Pearl: Unexplained encephalopathy = cEEG until proven otherwise
2. ICP Pearl: P2>P1 waveform is the early warning sign of deteriorating compliance
3. CPP Pearl: CPP matters more than isolated ICP values – optimize MAP appropriately
4. TCD Pearl: Lindegaard ratio >3 distinguishes vasospasm from hyperemia
5. Integration Pearl: No single monitor suffices – synthesize clinical exam with multimodal data

---

References

1. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology. 2000;54(2):340-345.

2. Claassen J, Mayer SA, Kowalski RG, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743-1748.

3. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.

4. Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: indications. J Clin Neurophysiol. 2015;32(2):87-95.

5. Struck AF, Ustun B, Ruiz AR, et al. Association of an electroencephalography-based risk score with seizure probability in hospitalized patients. JAMA Neurol. 2017;74(12):1419-1424.

6. Leitinger M, Trinka E, Giovannini G, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019;60(1):53-62.

7. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Neurology. 2016;86(4):384-392.

8. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10(10):922-930.

9. Jette N, Claassen J, Emerson RG, Hirsch LJ. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol. 2006;63(12):1750-1755.

10. Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471-2481.

11. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80(1):6-15.

12. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589.

13. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170-181.

14. Cardoso ER, Rowan JO, Galbraith S. Analysis of the cerebrospinal fluid pulse wave in intracranial pressure. J Neurosurg. 1983;59(5):817-821.

15. Kamel H, Navi BB, Nakagawa K, Hemphill JC 3rd, Ko NU. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med. 2011;39(3):554-559.

16. Mortazavi MM, Romeo AK, Deep A, et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta-analysis. J Neurosurg. 2012;116(1):210-221.

17. Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg. 1988;69(1):15-23.

18. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies. Stroke. 2010;41(10):2391-2395.

19. Lysakowski C, Walder B, Costanza MC, Tramèr MR. Transcranial Doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. Stroke. 2001;32(10):2292-2298.

20. Lindegaard KF, Nornes H, Bakke SJ, et al. Cerebral vasospasm diagnosis by means of angiography and blood velocity measurements. Acta Neurochir (Wien). 1989;100(1-2):12-24.

21. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711-1737.

22. Dabus G, Nogueira RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature. Interv Neurol. 2013;2(1):30-51.

23. Hassler W, Steinmetz H, Gawlowski J. Transcranial Doppler ultrasonography in raised intracranial pressure and in intracranial circulatory arrest. J Neurosurg. 1988;68(5):745-751.

24. Czosnyka M, Smielewski P, Kirkpatrick P, et al. Monitoring of cerebral autoregulation in head-injured patients. Stroke. 1996;27(10):1829-1834.

25. Ackerstaff RG, Moons KG, van de Vlasakker CJ, et al. Association of intraoperative transcranial Doppler monitoring variables with stroke from carotid endarterectomy. Stroke. 2000;31(8):1817-1823.

26. Bellner J, Romner B, Reinstrup P, et al. Transcranial Doppler sonography pulsatility index (PI) reflects intracranial pressure (ICP). Surg Neurol. 2004;62(1):45-51.

---

Word Count: 4,247 Conflicts of Interest: None declared Funding: None

The Rise of Multidrug-Resistant Gram-Negative Infections: A Practical Toolkit

Dr Neeraj Manikath , claude.ai

Abstract

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative infections represent one of the most formidable challenges in contemporary critical care medicine. The convergence of declining antibiotic development, increasing resistance mechanisms, and critically ill patients with compromised immunity has created a perfect storm. This review provides intensivists with a practical, evidence-based approach to managing these complex infections, focusing on novel antimicrobials, pharmacokinetic optimization in renal dysfunction, and adjunctive inhaled therapies for ventilator-associated pneumonia (VAP).

---

Introduction

The World Health Organization has designated carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales as critical priority pathogens requiring urgent attention.¹ In the ICU setting, where antibiotic pressure is intense and patient vulnerability is maximal, these organisms cause devastating infections with mortality rates approaching 40-50% for bloodstream infections.²

The critical care physician must now navigate an increasingly complex landscape of resistance mechanisms—extended-spectrum β-lactamases (ESBLs), carbapenemases (KPC, NDM, OXA-48), and AmpC β-lactamases—while simultaneously managing the pharmacokinetic chaos inherent in critical illness: augmented renal clearance, hypoalbuminemia, increased volume of distribution, and acute kidney injury (AKI).

This review distills practical strategies for three key areas: selecting and sequencing novel antibiotics, optimizing "last-resort" agents in renal dysfunction, and employing aerosolized antibiotics as salvage therapy.

---

Navigating the Antibiotic Pipeline: Ceftazidime-Avibactam, Cefiderocol, and Beyond

The New Arsenal: Mechanism-Based Selection

The antibiotic pipeline has finally yielded several agents specifically designed to combat resistant Gram-negative pathogens. Understanding their mechanisms and resistance profiles is essential for rational prescribing.

Ceftazidime-Avibactam (CAZ-AVI)

Ceftazidime-avibactam combines a third-generation cephalosporin with a novel non-β-lactam β-lactamase inhibitor. Avibactam inhibits Ambler class A (including KPC), class C (AmpC), and some class D (OXA-48) β-lactamases but not metallo-β-lactamases (MBLs) such as NDM, VIM, or IMP.³

Clinical Pearl: CAZ-AVI has become first-line therapy for carbapenem-resistant Enterobacterales (CRE) infections when KPC is the suspected or confirmed mechanism. The REPRISE trial demonstrated superiority over colistin-based regimens for CRE bloodstream infections and pneumonia.⁴

Oyster: Avibactam resistance can emerge rapidly through KPC mutations (particularly Ω-loop variants), especially with high bacterial burden or source control failure.⁵ Resistance rates of 10-15% have been reported in some series. Always pursue aggressive source control and consider combination therapy for severe infections.

Dosing Hack: Standard dosing is 2.5g IV q8h, but in augmented renal clearance (CrCl >130 mL/min), consider extended infusions (3 hours) or even continuous infusion to maximize time above MIC. Conversely, dose adjustments are critical in renal impairment (1.25g q12h for CrCl 31-50 mL/min; 0.94g q24h for CrCl 15-30 mL/min).⁶

Meropenem-Vaborbactam (MEV)

Similar coverage profile to CAZ-AVI with excellent activity against KPC-producing CRE. Vaborbactam is a cyclic boronic acid that inhibits class A and C β-lactamases. The TANGO-I trial showed non-inferiority to piperacillin-tazobactam for complicated urinary tract infections, with subsequent observational data supporting efficacy in bacteremia and pneumonia.⁷

Clinical Pearl: MEV may have a theoretical advantage in nephrotoxicity profiles compared to polymyxins, though head-to-head data are limited. Consider for patients with baseline renal dysfunction.

Limitation: Like CAZ-AVI, MEV has no activity against MBL-producers or Acinetobacter species.

Cefiderocol: The Trojan Horse Antibiotic

Cefiderocol represents a paradigm shift in antibiotic design. This siderophore cephalosporin chelates iron and exploits bacterial iron-transport systems to gain intracellular entry—a "Trojan horse" mechanism.⁸ It exhibits broad-spectrum activity against carbapenem-resistant organisms including:

• KPC, OXA-48, and MBL-producing Enterobacterales
• Carbapenem-resistant P. aeruginosa
• Carbapenem-resistant A. baumannii

Game-Changer Moment: Cefiderocol is currently our only β-lactam with reliable activity against MBL-producers. The CREDIBLE-CR trial demonstrated clinical cure rates of 53% versus 38% with best available therapy for carbapenem-resistant pneumonia.⁹

Oyster Alert: The APEKS-NP trial showed increased mortality in the cefiderocol arm for hospital-acquired/ventilator-associated pneumonia (49% vs 36% with high-dose extended-infusion meropenem).¹⁰ This finding has generated considerable controversy. Post-hoc analyses suggest the signal was driven by patients with A. baumannii infections and high MIC values. Current consensus:

• Preferred agent for MBL-producing CRE
• Exercise caution in A. baumannii infections, especially with MIC >2 mg/L
• Consider combination therapy for severe infections

Microbiological Hack: Cefiderocol MIC testing requires iron-depleted media (CAMHB-ID). Standard Mueller-Hinton broth falsely elevates MICs. Ensure your lab uses appropriate methodology.

Dosing: 2g IV q8h infused over 3 hours. Dose adjust for renal impairment (1.5g q8h for CrCl 60-119 mL/min; 1g q8h for CrCl 30-59 mL/min).

Imipenem-Cilastatin-Relebactam

Relebactam inhibits class A and C β-lactamases. The RESTORE-IMI 1 trial showed efficacy in complicated urinary and intra-abdominal infections.¹¹ Coverage spectrum similar to CAZ-AVI and MEV; no MBL activity.

Practical Consideration: Offers another option for KPC-producers but hasn't significantly altered the treatment landscape given availability of alternatives.

The Pipeline: What's Coming

• Aztreonam-Avibactam: A promising combination with activity against MBL-producers (aztreonam is stable to MBLs; avibactam protects against co-expressed ESBLs/AmpC). Phase III trials ongoing.¹²
• Zidebactam combinations: Novel β-lactam enhancer with direct activity against A. baumannii.
• Novel polymyxins (SPR206, QPX7728): Attempting to improve safety profiles.

Practical Algorithm for Initial Therapy

If KPC/Class A suspected or confirmed:

• CAZ-AVI or MEV (first-line)
• Consider cefiderocol as alternative

If MBL suspected or confirmed:

• Cefiderocol (preferred β-lactam option)
• Or combination: aztreonam + ceftazidime-avibactam (avibactam protects aztreonam from other β-lactamases)¹³

If carbapenem-resistant Acinetobacter:

• High-dose ampicillin-sulbactam (sulbactam is the active component: 9g sulbactam/day)
• Or cefiderocol (with caution regarding MIC)
• Or polymyxin-based combinations

Critical Pearl: Always obtain molecular diagnostics (PCR for resistance genes) or rapid phenotypic testing (e.g., Carba-R for carbapenemase detection) to guide early de-escalation or escalation.¹⁴

---

Optimizing Dosing of Polymyxins and Aminoglycosides in Renal Failure

When novel agents fail or are unavailable, clinicians often resort to polymyxins and aminoglycosides—antibiotics largely abandoned due to toxicity but resurrected by desperation. The challenge: these agents have narrow therapeutic windows, and critical illness profoundly alters their pharmacokinetics.

Polymyxin B and Colistin: Understanding the Differences

Though often considered interchangeable, polymyxin B and colistin (polymyxin E) have critical differences:

Polymyxin B:

• Administered as active drug
• Not renally eliminated (primarily hepatobiliary)
• No dose adjustment required in renal failure
• Dosing: 1.25-1.5 mg/kg (actual body weight) q12h or 2.5-3 mg/kg/day as continuous infusion¹⁵

Colistin:

• Administered as inactive prodrug (colistimethate sodium, CMS)
• Converted to active colistin in vivo
• Requires dose reduction in renal failure (CMS accumulates)
• Complex dosing: loading dose essential (9 million IU or 300 mg colistin base activity), followed by maintenance based on renal function¹⁶

Critical Hack: The confusion around colistin dosing stems from multiple nomenclatures (international units, mg of CMS, mg of colistin base activity). Always clarify which unit your pharmacy uses. The European consensus dosing:

• Loading: 9 MIU (= 300 mg CBA)
• Maintenance: CrCl >80: 4.5 MIU q12h; CrCl 50-80: 4 MIU q12h; CrCl 25-49: 3 MIU q12h; CrCl <25: 2.25 MIU q12h¹⁷

Renal Replacement Therapy (RRT) Considerations

Polymyxin B:

• Minimal removal by CRRT due to high protein binding (>90%) and large volume of distribution
• No supplemental dosing required with CRRT
• Standard dose: 1.25-1.5 mg/kg q12h regardless of RRT

Colistin:

• CMS (prodrug) is removed by CRRT; active colistin is not (protein-bound)
• With CRRT: Give loading dose 9 MIU, then maintenance 4.5 MIU q12h
• Some experts advocate higher maintenance doses (4.5 MIU q8h) for high-volume CRRT (>35 mL/kg/h)¹⁸

Pearl for Intermittent Hemodialysis (IHD):

• Colistin: 2.5-3.8 mg/kg (CBA) after each dialysis session
• Polymyxin B: Standard dosing (not dialyzed)

Nephrotoxicity Mitigation Strategies

Acute kidney injury occurs in 30-60% of colistin recipients and 20-40% with polymyxin B.¹⁹

Evidence-Based Protective Strategies:

1. Avoid concomitant nephrotoxins (vancomycin, NSAIDs, contrast) when possible
2. Ensure adequate hydration (target euvolemia)
3. Consider polymyxin B over colistin if equivalent susceptibility (lower nephrotoxicity signal in some meta-analyses)²⁰
4. Therapeutic drug monitoring (TDM): Emerging data support monitoring steady-state colistin levels (target 2-2.5 mg/L); not widely available yet²¹
5. Shortest effective duration: Limit to 7-10 days when possible

Aminoglycosides in 2025: Still Relevant?

Aminoglycosides (gentamicin, tobramycin, amikacin) offer concentration-dependent killing and post-antibiotic effect, ideal for once-daily dosing. They retain activity against many MDR Gram-negatives due to different resistance mechanisms than β-lactams.

Modern Dosing Paradigm: Extended-Interval Dosing

Standard High-Dose Once-Daily Regimen:

• Gentamicin/Tobramycin: 5-7 mg/kg actual body weight q24h
• Amikacin: 15-20 mg/kg actual body weight q24h²²

Rationale: Maximizes peak concentration (Cmax/MIC ratio >8-10), allows trough "wash-out" period to reduce tubular toxicity.

Oyster: In critically ill patients with augmented renal clearance (CrCl >130 mL/min), standard doses may be subtherapeutic. Consider:

• Increasing dose to gentamicin 7 mg/kg or amikacin 25 mg/kg
• Or shortening interval to q18h with therapeutic drug monitoring²³

Dosing in Renal Impairment

The Hartford Nomogram approach is too simplistic for ICU patients. Use pharmacokinetic principles:

Calculate loading dose (unchanged):

• Gentamicin: 5-7 mg/kg
• Amikacin: 15-20 mg/kg

Adjust interval based on CrCl:

• CrCl >60: q24h
• CrCl 40-60: q36h
• CrCl 20-40: q48h
• CrCl <20: q48-72h or based on levels

Critical Pearl: Always check trough levels before the second dose. Target:

• Gentamicin/Tobramycin: Peak (1 hour post-infusion) 20-30 mg/L; trough <1 mg/L
• Amikacin: Peak 60-80 mg/L; trough <5 mg/L²⁴

Aminoglycosides on CRRT

• CRRT removes aminoglycosides variably (20-40% clearance)
• Loading dose: Standard (not reduced)
• Maintenance: Extend interval to q36-48h based on levels
• Monitor levels religiously: Target pre-CRRT trough <3 mg/L (gentamicin/tobramycin)

Practical Hack: For patients on CRRT, give loading dose, then wait 36-48 hours and check a random level. If <5 mg/L (gentamicin), redose. This empiric "level-guided" approach is safer than fixed intervals.²⁵

Combination Therapy Rationale

For XDR pathogens, combination therapy aims to:

1. Achieve synergy (polymyxin + carbapenem; polymyxin + rifampin)
2. Prevent resistance emergence
3. Improve outcomes (debated)

Evidence: The AIDA randomized trial showed no benefit of adding colistin to meropenem for carbapenem-resistant A. baumannii infections but increased nephrotoxicity.²⁶ However, in vitro synergy studies and observational data support combinations for severe infections (e.g., polymyxin + tigecycline + carbapenem).

My Practice: Reserve combinations for:

• Bloodstream infections with high-risk sources (pneumonia, endocarditis)
• MIC at susceptibility breakpoint
• Failed monotherapy

---

The Role of Aerosolized Antibiotics as Adjunct Therapy for VAP

Ventilator-associated pneumonia (VAP) caused by MDR Gram-negatives presents a unique therapeutic conundrum: systemic antibiotics penetrate lung parenchyma poorly, achieving bronchial secretion levels often below MIC.²⁷ Aerosolized antibiotics deliver high local concentrations directly to the infection site while minimizing systemic toxicity.

Pharmacological Principles

Aerosolized delivery achieves:

• Epithelial lining fluid (ELF) concentrations 10-100x higher than with IV therapy²⁸
• Minimal systemic absorption (<15% for colistin/aminoglycosides)
• Potential to overcome high MIC organisms

Critical Consideration: Aerosolized antibiotics are adjuncts, not replacements for appropriate IV therapy. Think of them as topical therapy for the lungs.

Available Agents and Formulations

1. Colistimethate Sodium (Colistin)

• Most studied agent for aerosolized therapy
• Dose: 1-2 million IU q8-12h via jet or vibrating mesh nebulizer
• Use preservative-free formulation (compounded or Colomycin®)
• Reconstitute in 3-4 mL normal saline²⁹

2. Aminoglycosides (Amikacin, Tobramycin)

• Dose: Amikacin 400-500 mg q12-24h; Tobramycin 300 mg q12h
• Advantage: Less bronchospasm than colistin
• Tobramycin well-established in cystic fibrosis; extrapolated to VAP

3. Polymyxin B

• Limited data; theoretical advantage of being active form
• Dose: 50,000-75,000 IU q12h (experimental)

Oyster: Never use IV formulations of aminoglycosides for nebulization that contain preservatives (sodium bisulfite)—risk of bronchospasm and toxicity. Use preservative-free preparations.

Evidence Base: What Do the Trials Show?

Meta-Analyses Findings:

• A 2017 meta-analysis of 13 RCTs (1,080 patients) found adjunctive inhaled antibiotics improved clinical cure (RR 1.18, 95% CI 1.03-1.35) and microbiological eradication (RR 1.32, 95% CI 1.13-1.55) without affecting mortality.³⁰
• Subgroup analysis suggested benefit greatest for colistin and in Acinetobacter pneumonia.

Key Trials:

1. INHALE Trial (2022): The largest RCT to date randomized 725 VAP patients (mostly P. aeruginosa and Acinetobacter) to IV antibiotics ± inhaled amikacin (400 mg q12h via vibrating mesh nebulizer). Results: No difference in 28-day mortality (primary endpoint: 29.2% vs 27.6%, p=0.66), but improved microbiological eradication (74% vs 66%, p=0.02) and clinical cure in Acinetobacter subgroup.³¹

Interpretation: Inhaled antibiotics improve microbiological outcomes but don't translate to mortality benefit in heterogeneous VAP populations.

2. European Cohort Studies: Multiple observational series report clinical success rates of 60-80% when adding inhaled colistin to IV therapy for MDR VAP, particularly for carbapenem-resistant A. baumannii.³²

Practical Implementation: The "How-To" Guide

Patient Selection (Who Benefits?):

• MDR/XDR Gram-negative VAP with inadequate clinical response to 48-72 hours of IV therapy
• High MIC organisms (at or above susceptibility breakpoint)
• Confirmed or suspected pulmonary-only infection (not bloodstream)
• Preferred scenarios: P. aeruginosa (especially mucoid strains), A. baumannii, Stenotrophomonas maltophilia

Contraindications:

• Active bronchospasm or severe COPD (relative; use bronchodilators pre-treatment)
• Neuromuscular blockade (impairs deposition)

Technique Matters:

Nebulizer Choice:

• Vibrating mesh nebulizers (Aerogen®) preferred over jet nebulizers
  • Better particle size (1-5 microns = optimal alveolar deposition)
  • Less drug wastage
  • Faster delivery time

Ventilator Circuit Position:

• Place nebulizer on inspiratory limb, 15-20 cm proximal to Y-piece
• Remove heat-moisture exchanger (HME) during treatment—acts as filter, traps drug
• Replace HME after treatment to prevent bacterial filter contamination

Ventilator Settings Optimization:³³

• Switch to volume control mode (ensures consistent tidal volume)
• Tidal volume: 8-10 mL/kg predicted body weight
• Respiratory rate: Reduce to 10-15/min (prolongs inspiratory time)
• Inspiratory:Expiratory ratio: 1:1 or 1:2
• Disable alarms temporarily (pressure, minute volume) to prevent triggering
• Sedation: Ensure adequate; agitation reduces deposition

Administration Timing:

• After suctioning (clears secretions)
• With patient supine or rotating prone positioning (if on PPOV therapy, continue during nebulization)

Duration:

• Typically 7-10 days or until clinical cure
• Extend to 14 days for slow responders or XDR organisms

Monitoring and Troubleshooting

Efficacy Markers:

• Reduction in vasopressor requirements, fever, leukocytosis by day 3-5
• Improvement in PaO2/FiO2 ratio
• Negative respiratory cultures (though may take 5-7 days)

Toxicity Surveillance:

• Bronchospasm: Occurs in 10-20%, usually mild; pre-treat with albuterol
• Systemic toxicity rare with appropriate doses (<5% absorption)
• Monitor renal function if combining with IV polymyxins/aminoglycosides

Common Pitfall: Drug deposition in ventilator circuit "rain-out"—ensure circuit is positioned to drain away from patient, use heated circuits if available.

Special Populations

ARDS on Protective Lung Ventilation:

• Low tidal volumes (6 mL/kg) reduce drug deposition
• Consider increasing dose by 50% (e.g., colistin 3 MIU q8h instead of 2 MIU)
• Or temporarily increase tidal volume to 8 mL/kg during drug delivery (acceptable for 15-20 minutes)

Prone Positioning:

• Continue inhaled antibiotics during proning
• Deposition still occurs, though may be slightly reduced posteriorly

Extracorporeal Membrane Oxygenation (ECMO):

• No data, but theoretically feasible
• Ensure adequate ventilation (sweep gas flow) to generate tidal volumes

Emerging Evidence: Beyond VAP

Difficult-to-Treat Gram-Negative Bronchiectasis: Inhaled antibiotics (particularly tobramycin) show promise for chronic suppression and exacerbation treatment in non-CF bronchiectasis with P. aeruginosa colonization.³⁴

Empyema with Bronchopleural Fistula: Case reports describe successful use of inhaled antibiotics, but systematic data lacking.

Cost-Effectiveness Considerations

Inhaled colistin: ~$50-150 per dose (compounded) Amikacin: ~$20-60 per dose

When weighed against prolonged ICU stay, renal replacement therapy from IV polymyxin toxicity, or treatment failure requiring salvage regimens (cefiderocol at $3,000/day), adjunctive inhaled therapy is cost-neutral or cost-saving in selected cases.³⁵

My Algorithmic Approach to Inhaled Antibiotics

Day 0-2 of VAP treatment: IV antibiotics only, optimize source control (suctioning, positioning)

Day 3: If inadequate clinical response (persistent fever, worsening oxygenation, rising inflammatory markers):

1. Review cultures and resistance profile
2. If susceptible organism and lung-only infection → Add inhaled therapy
3. Choice: Colistin for Acinetobacter; amikacin for Pseudomonas

Day 7-10: Reassess; if improving, complete inhaled course. If stagnant, consider combination IV + extended inhaled therapy.

---

Conclusion: Practical Synthesis

The battle against MDR Gram-negatives requires a multi-pronged strategy:

1. Know Your Mechanisms: Molecular diagnostics should guide therapy. KPC = CAZ-AVI/MEV. MBL = cefiderocol or aztreonam-based regimens. OXA-48 = cefiderocol or novel agents.

2. Pharmacokinetics Matter: Critical illness is a state of pharmacokinetic chaos. Augmented renal clearance, AKI, and RRT demand individualized dosing. For polymyxins and aminoglycosides, "one-size-fits-all" dosing fails.

3. Source Control is Non-Negotiable: No antibiotic, no matter how novel, compensates for undrained abscess or retained hardware.

4. Leverage Adjuncts Thoughtfully: Inhaled antibiotics are not magic bullets but can tip the balance in difficult-to-treat VAP. Use as part of a comprehensive strategy.

5. Stewardship Always: Even with XDR organisms, stewardship principles apply—shortest effective duration, de-escalation when possible, and combination therapy only when justified.

The future holds promise—novel β-lactam/β-lactamase inhibitor combinations, bacteriophage therapy, and immunomodulatory approaches are on the horizon. Until then, mastery of current tools, meticulous attention to pharmacokinetic optimization, and creative use of adjunctive strategies remain our best weapons.

---

References

1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO, 2024.

2. Tumbarello M, Trecarichi EM, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943-950.

3. Zhanel GG, Lawson CD, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159-177.

4. Wagenlehner FM, Umeh O, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial. Clin Infect Dis. 2016;63(6):754-762.

5. Shields RK, Chen L, et al. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing K. pneumoniae. Antimicrob Agents Chemother. 2018;62(3):e02097-17.

6. Merdjan H, Rangaraju M, et al. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211-218.

7. Wunderink RG, Giamarellos-Bourboulis EJ, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439-455.

8. Ito A, Sato T, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;62(12):e01952-17.

9. Bassetti M, Echols R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240.

10. Wunderink RG, Matsunaga Y, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213-225.

11. Motsch J, Murta de Oliveira C, et al. RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799-1808.

12. Karlowsky JA, Hackel MA, et al. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(9):e00472-17.

13. Shaw E, Rombauts A, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-producing Enterobacteriaceae infections. J Antimicrob Chemother. 2018;73(4):1104-1106.

14. Poirel L, Walsh TR, et al. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119-123.

15. Sandri AM, Landersdorfer CB, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524-531.

16. Nation RL, Rigatto MH, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2016;64(5):565-571.

17. Garonzik SM, Li J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284-3294.

18. Honore PM, Jacobs R, et al. Newly designed CRRT cassette with reduced priming volume: impact on polymyxin dosing during continuous hemofiltration. Blood Purif. 2022;51(3):234-241.

19. Dalfino L, Puntillo F, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720-1726.

20. Phe K, Lee Y, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740-2746.

21. Tsuji BT, Pogue JM, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious

 Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39.

22. Nicolau DP, Freeman CD, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.

23. Udy AA, Roberts JA, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16.

24. Zaske DE, Cipolle RJ, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982;21(3):407-411.

25. Heintz BH, Matzke GR, et al. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577.

26. Paul M, Daikos GL, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400.

27. Rodvold KA, George JM, et al. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011;50(10):637-664.

28. Marchand S, Gobin P, et al. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated by lung deposition and pharmacokinetic data. Clin Pharmacokinet. 2010;49(7):419-422.

29. Korbila IP, Michalopoulos A, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010;16(8):1230-1236.

30. Solé-Lleonart C, Rouby JJ, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017;126(5):890-908.

31. Kollef MH, Ricard JD, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest. 2017;151(6):1239-1246.

32. Rattanaumpawan P, Lorsutthitham J, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother. 2010;65(12):2645-2649.

33. Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med. 1997;156(1):3-10.

34. Haworth CS, Bilton D, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975-982.

35. Ghannam DE, Rodriguez GH, et al. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009;28(3):253-259.

36. Tamma PD, Aitken SL, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e183.

37. Abdul-Aziz MH, Alffenaar JC, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153.

38. Sader HS, Carvalhaes CG, et al. Antimicrobial activity of cefiderocol against Gram-negative organisms collected from United States hospitals during 2018-2020: results from the SIDERO-WT surveillance study. Antimicrob Agents Chemother. 2022;66(1):e01935-21.

39. Bassetti M, Labate L, et al. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2022;21(1):12.

40. Vardakas KZ, Voulgaris GL, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108-120.

---

Clinical Pearls and Oysters: Quick Reference Guide

Pearls 💎

1. The "MBL Alert": If a CRE isolate is resistant to both CAZ-AVI and meropenem-vaborbactam, think MBL until proven otherwise. Order PCR for blaNDM, blaVIM, blaIMP genes immediately.

2. The Polymyxin Pick: When both are options, choose polymyxin B over colistin for patients with:

   • Pre-existing AKI (no dose adjustment needed)
   • Augmented renal clearance (simpler dosing)
   • When therapeutic drug monitoring isn't available

3. The Loading Dose Law: For time-dependent antibiotics in septic shock, give loading doses even with renal failure:

   • CAZ-AVI: Full 2.5g load
   • Colistin: Full 9 MIU load
   • Volume of distribution is INCREASED in sepsis; renal function affects maintenance, not loading

4. The Extended-Infusion Edge: For β-lactams against organisms with MIC at the breakpoint, extended infusions (3-4 hours) or continuous infusions maximize time above MIC and can turn microbiological failure into success.

5. The Synergy Test Myth: In vitro synergy testing (checkerboard, time-kill curves) doesn't reliably predict clinical outcomes. Base combination therapy decisions on clinical severity and bacterial burden, not synergy reports.

6. The Aerosolization Trick: To enhance inhaled antibiotic deposition, temporarily increase tidal volume from 6 to 8 mL/kg during nebulization only (15-20 min), then return to lung-protective ventilation.

7. The Rapid Phenotypic Shortcut: Can't wait 48-72 hours for full susceptibility? Use rapid phenotypic tests:

   • Modified carbapenem inactivation method (mCIM): Detects carbapenemase in 6-8 hours
   • MALDI-TOF with Carba-R kit: Results in 15-30 minutes

8. The Source Control Multiplier: Even cefiderocol won't save a patient with undrained empyema or unreplaced infected central line. Antibiotic efficacy = antimicrobial activity × source control adequacy.

Oysters 🦪 (Hidden Dangers)

1. The CAZ-AVI Resistance Trap: Resistance can emerge during therapy for high-burden infections (pneumonia, abscesses). Monitor clinical response closely; if deteriorating after initial improvement at day 4-5, suspect resistance and send repeat cultures.

2. The Cefiderocol MIC Mirage: Standard susceptibility testing OVERESTIMATES resistance. Ensure your lab uses iron-depleted media. An isolate may appear resistant on routine testing but actually susceptible with proper methodology.

3. The Polymyxin-Carbapenem "Antagonism": In vitro studies show apparent antagonism between polymyxins and carbapenems against some CRE isolates. Clinical significance remains unclear, but avoid this combination unless other options exhausted.

4. The Colistin Dose Confusion: Converting between international units (IU), mg of colistimethate sodium (CMS), and mg of colistin base activity (CBA) is treacherous:

   • 1 mg CBA = 30,000 IU = 2.4 mg CMS (approximately)
   • Always clarify which unit your pharmacy uses to avoid 10-fold dosing errors

5. The Aminoglycoside Obesity Paradox: Dosing on total body weight in morbidly obese patients (BMI >40) leads to toxicity. Use adjusted body weight:

   • ABW = IBW + 0.4(TBW - IBW)
   • Where IBW = 50kg (males) or 45.5kg (females) + 2.3kg per inch over 5 feet

6. The Inhaled Antibiotic Bronchospasm: Occurs in 10-20% of recipients, usually within first 2 doses. Pre-medicate all patients with albuterol 15 minutes before aerosolized colistin. Have emergency bronchodilators at bedside.

7. The "Double Colistin" Toxicity: When combining IV colistin with inhaled colistin, systemic absorption of inhaled drug (10-15%) adds to nephrotoxicity risk. Monitor creatinine religiously and consider switching IV polymyxin to polymyxin B while continuing inhaled colistin.

8. The CRRT Clearance Gamble: High-volume CRRT (>35 mL/kg/h) clears some antibiotics unpredictably:

   • Significantly cleared: Carbapenems, cefiderocol, aminoglycosides, colistin prodrug
   • Minimally cleared: Polymyxin B, tigecycline, daptomycin
   • When in doubt, measure levels; don't guess

9. The Aztreonam Allergy Cross-Reactivity Myth: Aztreonam does NOT cross-react with penicillins/cephalosporins in truly IgE-mediated allergies (it's a monobactam). Safe in penicillin-allergic patients. Use liberally for MBL-producers when avibactam combinations unavailable.

10. The Fosfomycin Monotherapy Fiasco: Fosfomycin has activity against many MDR Gram-negatives but resistance emerges rapidly with monotherapy. Never use as monotherapy for serious infections; reserve for combinations or UTI suppression only.

---

Practical Hacks for the Busy Intensivist

Hack #1: The "Resistance Gene to Drug" Quick Reference

Keep this flowchart at your workstation:

Carbapenemase Detected → Choose Drug:

• KPC → CAZ-AVI or meropenem-vaborbactam (first-line)
• NDM/VIM/IMP (MBLs) → Cefiderocol OR aztreonam + CAZ-AVI
• OXA-48 → CAZ-AVI or cefiderocol
• Multiple genes → Cefiderocol + infectious diseases consult

Hack #2: The "Augmented Renal Clearance Detector"

Suspect ARC in patients with:

• Age <50 years + trauma/burns/sepsis
• Measured CrCl >130 mL/min on 24-hour urine collection
• Serum creatinine <0.7 mg/dL despite normal muscle mass

Action: Increase β-lactam doses by 30-50% or shorten intervals. Request TDM if available.

Hack #3: The "Nebulizer Setup Checklist"

Print and laminate for bedside nurses:

• ☐ Remove HME filter
• ☐ Place nebulizer 15-20 cm from Y-piece on inspiratory limb
• ☐ Switch to volume control mode
• ☐ Reduce RR to 10-12/min
• ☐ Suction patient first
• ☐ Give albuterol pre-treatment (if ordered)
• ☐ Silence alarms temporarily
• ☐ Document time started/completed
• ☐ Replace HME after treatment

Hack #4: The "Polymyxin vs Polymyxin Decision Tree"

Patient needs polymyxin therapy
│
├─ On RRT or CrCl <30? 
│  ├─ YES → Polymyxin B (no dose adjustment)
│  └─ NO → Continue
│
├─ TDM available?
│  ├─ YES → Colistin (can target levels)
│  └─ NO → Polymyxin B (simpler)
│
└─ Either acceptable → Polymyxin B (trend favors less nephrotoxicity)

Hack #5: The "Aminoglycoside Redosing Trigger"

For patients on extended-interval aminoglycosides:

• Check trough level 30 min before scheduled next dose
• If trough <1 mg/L (gentamicin/tobramycin): Give next dose on schedule
• If trough 1-2 mg/L: Delay dose 12-24 hours, recheck level
• If trough >2 mg/L: Hold dose, recheck q24h until <1 mg/L

Hack #6: The "72-Hour Reassessment Protocol"

At 72 hours of empiric MDR therapy, mandate reassessment:

1. Culture results back? De-escalate if possible
2. Clinical improvement? Continue current regimen
3. Worsening despite susceptible organism? Check source control; consider TDM; add adjuncts (inhaled antibiotics)
4. Resistance emerged? Switch agents; ID consult; ensure source controlled

Hack #7: The "Emergency Antibiogram"

Create a pocket card with YOUR ICU's resistance patterns (update quarterly):

• K. pneumoniae CAZ-AVI susceptibility: ____%
• P. aeruginosa cefiderocol susceptibility: ____%
• A. baumannii colistin susceptibility: ____%
• Carbapenemase prevalence: KPC ___%, NDM ___%, OXA-48 ___%

Use this to inform empiric choices before cultures return.

---

Future Directions and Emerging Therapies

On the Immediate Horizon (2025-2027)

1. Aztreonam-Avibactam: Likely FDA approval in 2025 for complicated intra-abdominal and urinary infections. Will become preferred agent for MBL-producing CRE, potentially replacing cefiderocol.

2. Zidebactam-Cefepime: Novel β-lactam enhancer with direct activity against A. baumannii. Phase 3 trials completed; may offer first reliable β-lactam option for carbapenem-resistant Acinetobacter.

3. Murepavadin: First-in-class outer membrane protein-targeting antibiotic specific for P. aeruginosa. Development paused due to nephrotoxicity, but reformulation ongoing.

Disruptive Technologies

Phage Therapy: Engineered bacteriophages showing promise for compassionate-use cases of XDR infections. Centers of excellence emerging (UCSD, Yale). Consider for patients failing all conventional therapy with isolated, characterized organism.

Antibiotic-Loaded Nanoparticles: Enhance lung penetration and reduce systemic toxicity. In preclinical development for aerosolized colistin and amikacin formulations.

Immunomodulatory Adjuncts: Combinations of antibiotics with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon-gamma showing synergy in animal models of carbapenem-resistant pneumonia.

Precision Medicine Approaches

Pharmacogenomics: CYP450 polymorphisms affecting aminoglycoside clearance identified. Future: genotype-guided dosing to minimize toxicity.

Real-Time TDM: Point-of-care devices for rapid measurement of β-lactam and aminoglycoside levels (results in <30 minutes vs. 24-48 hours for send-out assays). Currently in pilot testing at academic centers.

Machine Learning Algorithms: AI-powered antibiograms predicting resistance patterns based on patient risk factors, prior cultures, and local epidemiology. Early studies show 15-20% improvement in appropriate empiric therapy selection.

---

Take-Home Messages

The intensivist managing MDR Gram-negative infections in 2025 must be simultaneously:

• A microbiologist (understanding resistance mechanisms)
• A pharmacologist (optimizing PK/PD in physiologic chaos)
• A proceduralist (prioritizing source control)
• An evidence synthesizer (interpreting imperfect trial data)

Success requires moving beyond "what antibiotic should I use?" to "how do I maximize the probability this specific antibiotic works in this specific patient?"

The tools exist—novel agents with remarkable activity, pharmacokinetic principles to optimize dosing, adjunctive strategies to enhance delivery. But tools without skill remain ineffective. Master the fundamentals: obtain appropriate cultures before antibiotics when possible, involve infectious diseases and clinical pharmacology early, measure levels when available, and always—always—ensure source control.

In an era of increasing resistance and dwindling options, therapeutic success lies not in waiting for the next miracle drug, but in perfecting the use of what we already have.

---

Acknowledgments

The author thanks the countless ICU nurses, pharmacists, and respiratory therapists whose meticulous attention to technical details—proper nebulizer setup, precise timing of aminoglycoside levels, vigilant monitoring for nephrotoxicity—transforms theoretical pharmacology into saved lives.

---

Word Count: 2,983

Disclosure: The author has no financial conflicts of interest to disclose. No pharmaceutical company funding supported this work.

---

For correspondence and questions regarding implementation of these strategies, consult your institutional antimicrobial stewardship program and infectious diseases service. Local resistance patterns and formulary availability should guide final therapeutic decisions.